Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab single-dose placebo-controlled trial in systemic juvenile idiopathic arthritis
NL-OMON35316Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic juvenile idiopathic arthritis (SJIA) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2009; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON35316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35316.